Management of laryngopharyngeal reflux with proton pump inhibitors

Therapeutics and Clinical Risk Management

Volumn 4, Issue 1, 2008, Pages 225-233

  Reimer, Christina ^a   Bytzer, Peter ^a  

^a University of Køge   (Denmark)

Author keywords

Laryngopharyngeal reflux; Proton pump inhibitor

Indexed keywords

ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; RABEPRAZOLE;

CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; HEARTBURN; HUMAN; LARYNGOPHARYNGEAL REFLUX; LARYNGOSCOPY; LIFESTYLE MODIFICATION; MORNING DOSAGE; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PH MEASUREMENT; QUALITY OF LIFE; REFLUX ESOPHAGITIS; REMISSION; REVIEW;

EID: 41549086997     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Ahmed TF, Khandwala F, Abelson TI, et al. 2006. Chronic laryngitis associated with gastroesophageal reflux: prospective assessment of differences in practice patterns between gastroenterologists and ENT physicians. Am J Gastroenterol, 101:470-8.
2. Belafsky PC, Postma GN, Koufman JA. 2001. Laryngopharyngeal reflux symptoms improve before changes in physical findings. Laryngoscope, 111:979-81.
3. Belafsky PC, Postma GN, Koufman JA. 2002. Validity and reliability of the reflux symptom index (RSI). J Voice, 16:274-7.
4. Branski RC, Bhattacharyya N, Shapiro J. 2002. The reliability of the assessment of endoscopic laryngeal findings associated with laryngopharyngeal reflux disease. Laryngoscope, 112:1019-24.
5. Bytzer P. 2006. Introduction: pharmacodynamic and pharmacokinetic properties of proton pump inhibitors and their clinical impact - focus on rabeprazole. Aliment Pharmacol Ther symp ser, 2:311-3.
6. Carrau RL, Khidr A, Crawley JA, et al. 2004. The impact of laryngopharyngeal reflux on patient-reported quality of life. Laryngoscope, 114:670-4.
7. Carrau RL, Khidr A, Gold KF, et al. 2005. Validation of a quality-of-life instrument for laryngopharyngeal reflux. Arch Otolaryngol Head Neck Surg, 131:315-20.
8. Chiba N, De Gara CJ, Wilkinson JM, et al. 1997. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology, 112:1798-810.
9. Delgaudio JM, Waring JP. 2003. Empiric esomeprazole in the treatment of laryngopharyngeal reflux. Laryngoscope, 113:598-601.
10. Dore MP, Pedroni A, Pes GM, et al. 2007. Effect of antisecretory therapy on atypical symptoms in gastroesophageal reflux disease. Dig Dis Sci, 52:463-8.
11. Eherer AJ, Habermann W, Hammer HF, et al. 2003. Effect of pantoprazole on the course of reflux-associated laryngitis: a placebo-controlled double-blind crossover study. Scand J Gastroenterol, 38:462-7.
12. El-Serag HB, Lee P, Buchner A, et al. 2001. Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial. Am J Gastroenterol, 96:979-83.
13. Ford CN. 2005. Evaluation and management of laryngopharyngeal reflux. JAMA, 294:1534-40.
14. Gatta L, Vaira D, Sorrenti G, et al. 2007. Meta-analysis: the efficacy of proton pump inhibitors for laryngeal symptoms attributed to gastro-oesophageal reflux disease. Aliment Pharmacol Ther, 25:385-92.
15. Gerson LB, Triadafilopoulos G. 2001. Proton pump inhibitors and their drug interactions: an evidence-based approach. Eur J Gastroenterol Hepatol, 13:611-6.
16. Habermann W, Eherer A, Lindbichler F, et al. 1999. Exjuvantibus approach for chronic posterior laryngitis: results of short-term pantoprazole therapy. J Laryngol Otol, 113:734-9.
17. Habermann W, Kiesler K, Eherer A, et al. 2002. Short-term therapeutic trial of proton pump inhibitors in suspected extraesophageal reflux. J Voice, 16:425-32.
18. Hanson DG, Kamel PL, Kahrilas PJ. 1995. Outcomes of antireflux therapy for the treatment of chronic laryngitis. Ann Otol Rhinol Laryngol, 104:550-5.
19. Havas T, Huang S, Levy M. 1999. Double blind randomized placebo-controlled trial of proton pump inhibitor therapy. Aust J Otolaryngol, 3:243-6.
20. Hicks DM, Ours TM, Abelson TI, et al. 2002. The prevalence of hypopharynx findings associated with gastroesophageal reflux in normal volunteers. J Voice, 16:564-79.
21. Horn J. 2000. The proton-pump inhibitors: similarities and differences. Clin Ther, 22:266-80.
22. Jaspersen D, Weber R, Hammar CH, et al. 1996. Effect of omeprazole on the course of associated esophagitis and laryngitis. J Gastroenterol, 31:765-7.
23. Jones R, Bytzer P. 2001. Review article: acid suppression in the management of gastro-oesophageal reflux disease-an appraisal of treatment options in primary care. Aliment Pharmacol Ther, 15:765-72.
24. Kamel PL, Hanson D, Kahrilas PJ. 1994. Omeprazole for the treatment of posterior laryngitis. Am J Med, 96:321-6.
25. Kromer W, Horbach S, Luhmann R. 1999. Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis. Pharmacology, 59:57-77.
26. Langevin S, Hanh N. 2001. GERD-induced ENT symptoms: A prospective placebo controlled study with omeprazole 40 mg a day. Gastroenterology, 120:A16.
27. Noordzij JP, Khidr A, Evans BA, et al. 2001. Evaluation of omeprazole in the treatment of reflux laryngitis: a prospective, placebo-controlled, randomized, double-blind study. Laryngoscope, 111:2147-51.
28. Ours TM, Kavuru MS, Schilz RJ, et al. 1999. A prospective evaluation of esophageal testing and a double-blind, randomized study of omeprazole in a diagnostic and therapeutic algorithm for chronic cough. Am J Gastroenterol, 94:3131-8.
29. Park W, Hicks DM, Khandwala F, et al. 2005. Laryngopharyngeal reflux: prospective cohort study evaluating optimal dose of proton-pump inhibitor therapy and pretherapy predictors of response. Laryngoscope, 115:1230-8.
30. Qadeer MA, Phillips CO, Lopez AR, et al. 2006. Proton pump inhibitor therapy for suspected GERD-related chronic laryngitis: a meta-analysis of randomized controlled trials. Am J Gastroenterol, 101:2646-54.
31. Qua CS, Wong CH, Gopala K, et al. 2007. Gastro-oesophageal reflux disease in chronic laryngitis: prevalence and response to acid-suppressive therapy. Aliment Pharmacol Ther, 25:287-95.
32. Reilly JP. 1999. Safety profile of the proton-pump inhibitors. Am J Health Syst Pharm, 56:S11-S17.
33. Sachs G, Shin JM, Munson K, et al. 2000. Review article: the control of gastric acid and Helicobacter pylori eradication. Aliment Pharmacol Ther, 14:1383-401.
34. Shaw GY, Searl JP. 1997. Laryngeal manifestations of gastroesophageal reflux before and after treatment with omeprazole. South Med J, 90:1115-22.
35. Siupsinskiene N, Adamonis K, Toohill RJ. 2007. Quality of life in laryngopharyngeal reflux patients. Laryngoscope, 117:480-4.
36. Steward DL, Wilson KM, Kelly DH, et al. 2004. Proton pump inhibitor therapy for chronic laryngo-pharyngitis: a randomized placebo-control trial. Otolaryngol Head Neck Surg, 131:342-50.
37. Ulualp SO, Toohill RJ, Shaker R. 2001. Outcomes of acid suppressive therapy in patients with posterior laryngitis. Otolaryngol Head Neck Surg, 124:16-22.
38. Vaezi MF, Hicks DM, Abelson TI, et al. 2003. Laryngeal signs and symptoms and gastroesophageal reflux disease (GERD): a critical assessment of cause and effect association. Clin Gastroenterol Hepatol, 1:333-44.
39. Vaezi MF, Richter JE, Stasney CR, et al. 2006. Treatment of chronic posterior laryngitis with esomeprazole. Laryngoscope, 116:254-60.
40. Williams RB, Szczesniak MM, Maclean JC, et al. 2004. Predictors of outcome in an open label, therapeutic trial of high-dose omeprazole in laryngitis. Am J Gastroenterol, 99:777-85.
41. Wo JM, Grist WJ, Gussack G, et al. 1997. Empiric trial of high-dose omeprazole in patients with posterior laryngitis: a prospective study. Am J Gastroenterol, 92:2160-5.
42. Wo JM, Koopman J, Harrell SP, et al. 2006. Double-blind, placebo-controlled trial with single-dose pantoprazole for laryngopharyngeal reflux. Am J Gastroenterol, 101: 1972-8.